methenolone and Osteoporosis

Androgen inhibits osteoclastic bone resorption with increase of bone formation through androgen receptor in bone tissue. Anabolic steroids are synthetic derivates of testoterone. Anobolic steroids have favorable anabolic actions, lessening virilizing effects. Several anabolic steroids have been synthesized and some of them have been approved as a drug for anti osteoporosis. Anabolic steroids have revealed the increased bone mineral content or bone mineral density at the radius, and the lumbar spine in osteoporosis patients. Anabolic steroids have also decreased fat mass with increase of lean body mass and muscle mass, and lessened bone pain in osteoporosis patients having bone fracture, which seem to be favorable effects for especially elder osteoporosis patients. But in recent years the number of osteoporosis patients treated with anabolic steroids has been decreasing. Furthermore recently few clinical trials about the effect of anabolic steroids on osteoporosis have been reported, and prospective study for bone fracture using anabolic steroids has not reported yet. We would like to expect additional effects except on bone formation will enhance the frequency in use of anabolic steroids, and the prospective clinical study about the prevention against bone fracture will be reported in the future.

Topics: Adipose Tissue; Aged; Aged, 80 and over; Anabolic Agents; Bone Density; Clinical Trials as Topic; Evidence-Based Medicine; Fractures, Bone; Humans; Methenolone; Muscle, Skeletal; Nandrolone; Osteoporosis

Lateral radiographs of the thoracic and lumbar spine were taken periodically in 49 patients with osteoporosis. Thirty patients were postmenopausal, and 19 nonmenopausal with osteoporosis due to steroids, male hypogonadism, alcoholism, thyrotoxicosis or unknown cause. Patients were studied before, during and after treatment with high calcium alone, or with combined calcium and sex steroids. Calcium was given as effervescent calcium lactate gluconate, and sex hormones as oestradiol valerate, testosterone oenanthate, or methenolone oenanthate. A total of 964 films covering 409 patient-years were available for measurement. On each vertebra, deformity due to loss of anterior height was measured and assigned to one of four grades. For the time interval between each consecutive pair of films, a patient's vertebral fracture rate score was calculated and expressed per thousand patient-years. In comparison with the corresponding pretreatment fracture rate score, both the postmenopausal and the nonmenopausal groups who had not received sex hormones previously, failed to show significant changes (p = 0.144; p = 0.017) on high calcium alone during mean periods of 4.3 and 2.8 years respectively. If the first 2 years on high calcium were excluded for the postmenopausal group, they still failed to show a reduction in fracture rate score (observed for a mean period of 5.0 years; p = 0.04). When treated with combined calcium and sex hormones, both postmenopausal and nonmenopausal groups showed a lower fracture rate score of 20 and 207 respectively when compared with the pretreatment levels of 1500 and 1697 (in mean treatment periods of 3.2 and 4.4 years; p less than 0.001 in each case). When given high-dose calcium alone, but after treatment with sex hormones as well, the postmenopausal group showed no change in fracture rate score from pretreatment (in a mean of 3.1 years; p = 0.069); however the nonmenopausal group still showed a significant reduction in fracture rate score from 1697 to 42 over a mean period of 2.3 years (p = 0.001). The postmenopausal group, after stopping all treatment, showed a higher fracture rate score of 1286 (in a mean of 2.6 years) than did those on combined calcium and sex hormones, in whom the fracture rate score was 20 (in a mean of 3.2 years; p = 0.008). A subgroup of 11 patients with osteoporosis of both the menopausal and nonmenopausal types, had data both before (in a mean of 5.5 years) and during (for a mean of 2.5 years) treatment with c

Topics: Adult; Calcium; Drug Therapy, Combination; Estradiol; Estrogens, Conjugated (USP); Female; Gonadal Steroid Hormones; Humans; Male; Methenolone; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Spinal Fractures; Testosterone; Time Factors

Topics: Aged; Calcium; Drug Combinations; Female; Humans; Male; Methenolone; Middle Aged; Osteoporosis

Topics: Adolescent; Adrenal Insufficiency; Adrenocorticotropic Hormone; Adult; Age Factors; Aged; Calcium; Child; Child, Preschool; Female; Humans; Hydrocortisone; Male; Methenolone; Middle Aged; Nitrogen; Osteoporosis; Phosphorus; Protein Deficiency; Sex Factors; Testosterone

Topics: Adrenal Cortex Hormones; Anabolic Agents; Androgens; Antineoplastic Agents; Breast Neoplasms; Castration; Estrogens; Geriatrics; Humans; Lactones; Methenolone; Neoplasm Metastasis; Neoplasms; Osteoporosis; Steroids

Topics: Anabolic Agents; Animals; Carbon Tetrachloride; Collagen; Liver Cirrhosis; Methenolone; Osteoporosis; Rats; Sulfur Isotopes

Topics: Adult; Anabolic Agents; Female; Humans; Male; Methandrostenolone; Methenolone; Methyltestosterone; Middle Aged; Norethandrolone; Osteoporosis; Testosterone

Topics: Anabolic Agents; Calcium; Methenolone; Osteoporosis; Pharmacology; Rats; Research; Spine; Steroids; Testosterone